Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NC527-X in Intraoperative Imaging for Solid Tumors
NCT07538648Phase 1Recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Dec 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of NC527-X in solid tumor (4 arms), sponsored by Zhejiang Cancer Hospital. Primary endpoint: Signal-to-Background Ratio. Started Dec 2025; status: recruiting.
02
Drugs
NC527-X
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07538648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07538648.